Design and rationale of low-dose erythropoietin in patients with st-segment elevation myocardial infarction (epo-ami-ii study): A randomized controlled clinical trial

Cardiovascular Drugs and Therapy

Volumn 26, Issue 5, 2012, Pages 409-416

  Minamino, Tetsuo ^a   Toba, Ken ^c   Higo, Shuichiro ^a   Nakatani, Daisaku ^a   Hikoso, Shungo ^a   Umegaki, Masao ^b   Yamamoto, Kouji ^b   Sawa, Yoshiki ^a   Aizawa, Yoshifusa ^d   Komuro, Issei ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^d Tachikawa Medical Center   (Japan)

Author keywords

Acute myocardial infarction; Erythropoietin; Low dose; LV dysfunction

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NUMBERS NEEDED TO TREAT; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STUDY DESIGN;

ADULT; AGED; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 84868001728     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6410-4     Document Type: Article

References (29)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010;121:948-54.
2. Takii T, Yasuda S, Takahashi J, et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: Report from the MIYAGI-AMI Registry Study. Circ J. 2010;74:93-100.
3. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation. 2000;101:2981-8. (Pubitemid 30415891)
4. Minamino T. Cardioprotection from ischemia/reperfusion injury: Basic and translational research. Circ J. 2012;76:1074-82.
5. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev. 1992;72:449-89.
6. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther. 2005;19:33-40. (Pubitemid 40767770)
7. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006;48:176-84. (Pubitemid 43929217)
8. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, doubleblind trial. Circ Cardiovasc Interv. 2010;3:408-13.
9. Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J. 2010;31:2593-600.
10. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: A randomized controlled trial. JAMA. 2011;305:1863-72.
11. Ozawa T, Toba K, Suzuki H, et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study. Circ J. 2010;74:1415-23.
12. Taniguchi N, Nakamura T, Sawada T, et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after STelevated acute myocardial infarction (EPOC-AMI): A pilot, randomized, placebo-controlled study. Circ J. 2010;74:2365-71.
13. Opie LH. Erythropoietin as a cardioprotective agent: Down but not out. Heart. 2011;97:1537-9.
14. Vaziri ND. Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency. Am J Kidney Dis. 2009;53:733-6.
15. Baker JE, Kozik D, Hsu AK, Fu X, Tweddell JS, Gross GJ. Darbepoetin alfa protects the rat heart against infarction: Dose-response, phase of action, and mechanisms. J Cardiovasc Pharmacol. 2007;49:337-45. (Pubitemid 47000307)
16. Uesaka H. A personal view of methods of sample size estimation for a clinical trial. Jpn J Biom. 2003;24:17-41.
17. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton: Chapman & Hall/CRC; 2000.
18. Zhang J, Somani AK, Siminovitch KA. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol. 2000;12:361-78.
19. Kanellakis P, Pomilio G, Agrotis A, et al. Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor. Br J Pharmacol. 2010;160:2085-96.
20. Hausenloy DJ, Baxter G, Bell R, et al. Translating novel strategies for cardioprotection: The Hatter Workshop Recommendations. Basic Res Cardiol. 2010;105:677-86.
21. Schwartz Longacre L, Kloner RA, Arai AE, et al. New horizons in cardioprotection: Recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation. 2011;124:1172-9.
22. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J. 2009;73:1171-7.
23. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-81.
24. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: A randomised trial. Lancet. 2010;375:727-34.
25. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: Dose response and therapeutic window. Cardiovasc Drugs Ther. 2005;19:243-50. (Pubitemid 41778804)
26. Li J, Xu H, Gao Q, Wen Y. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: A systematic review. Eur J Clin Pharmacol. 2011;68:469-77.
27. Stein A,Mohr F, LauxM, et al. Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. Thromb Haemost. 2012;107:769-74.
28. Minamino T, Toba K, Higo S, Nakatani D, Ozawa T. Erythropoietin, progenitor cells and restenosis. A critique of Stein et al. Thromb Haemost. 2012;107:1193.
29. Carlsson M, Ubachs JF, Hedstrom E, Heiberg E, Jovinge S, Arheden H. Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging. 2009;2:569-76.